Table 5 Comparison of FDA-EUA and COVAM seropositivity and symptom characteristics among those with PCR-confirmed COVID
Seropositive and PCR-positives | FDA-EUA Assay or COVAM N (%) | FDA-EUA assay serology N (%) | COVAM serology N (%) | p valuea | |||
|---|---|---|---|---|---|---|---|
PCR-positive—total | 41 | 38 | 41 |  | |||
Seropositive | 41 | 38 | 41 | Â | |||
Reported to Occ health | 41 | 38 | 41 | Â | |||
No symptom reported | 4 | 9.8% | 4 | 10.5% | 4 | 9.8% | 0.81 |
Any symptom reported | 37 | 90.2% | 34 | 89.5% | 37 | 90.2% | 0.81 |
 Symptom type |  |  |  |  |  |  |  |
 Fever | 31 | 75.6% | 30 | 78.9% | 31 | 75.6% | 0.77 |
 Non febrile illness | 6 | 14.6% | 4 | 10.5% | 6 | 14.6% | 0.84 |
 Fatigue | 31 | 75.6% | 29 | 76.3% | 31 | 75.6% | 0.89 |
 Chills | 30 | 73.2% | 28 | 73.7% | 30 | 73.2% | 0.90 |
 Myalgia | 30 | 73.2% | 28 | 73.7% | 30 | 73.2% | 0.90 |
 Congestion | 21 | 51.2% | 19 | 50.0% | 21 | 51.2% | 0.94 |
Cough | 24 | 58.5% | 23 | 60.5% | 24 | 58.5% | 0.91 |
 Loss of smell | 27 | 65.9% | 26 | 68.4% | 27 | 65.9% | 0.87 |
 Shortness of breath | 15 | 36.6% | 14 | 36.8% | 15 | 36.6% | 0.93 |
Days between symptoms and serology sample collection | Â | Â | Â | Â | Â | Â | Â |
 < 14 days | 4 | 9.8% | 3 | 7.9% | 4 | 9.8% | 0.96 |
 15–29 days | 7 | 17.1% | 6 | 15.8% | 7 | 17.1% |  |
 30–44 days | 7 | 17.1% | 7 | 18.4% | 7 | 17.1% |  |
 45–59 days | 17 | 41.5% | 16 | 42.1% | 17 | 41.5% |  |
 60–74 days | 1 | 2.4% | 1 | 2.6% | 1 | 2.4% |  |
 ≥ 75 days | 1 | 2.4% | 1 | 2.6% | 1 | 2.4% |  |